- Home
- CMC vs RVMD Comparison
CMC vs RVMD Comparison
Compare CMC & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- RVMD
- Stock Information
- Founded
- CMC 1915
- RVMD 2014
- Country
- CMC United States
- RVMD United States
- Employees
- CMC N/A
- RVMD N/A
- Industry
- CMC Steel/Iron Ore
- RVMD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMC Industrials
- RVMD Health Care
- Exchange
- CMC Nasdaq
- RVMD Nasdaq
- Market Cap
- CMC 6.4B
- RVMD 7.5B
- IPO Year
- CMC 1987
- RVMD 2020
- Fundamental
- Price
- CMC $60.73
- RVMD $64.30
- Analyst Decision
- CMC Buy
- RVMD Strong Buy
- Analyst Count
- CMC 11
- RVMD 17
- Target Price
- CMC $63.91
- RVMD $77.24
- AVG Volume (30 Days)
- CMC 1.5M
- RVMD 2.4M
- Earning Date
- CMC 10-16-2025
- RVMD 11-05-2025
- Dividend Yield
- CMC 1.22%
- RVMD N/A
- EPS Growth
- CMC N/A
- RVMD N/A
- EPS
- CMC 0.74
- RVMD N/A
- Revenue
- CMC $7,798,480,000.00
- RVMD N/A
- Revenue This Year
- CMC $11.56
- RVMD N/A
- Revenue Next Year
- CMC $5.86
- RVMD $537.73
- P/E Ratio
- CMC $79.95
- RVMD N/A
- Revenue Growth
- CMC N/A
- RVMD N/A
- 52 Week Low
- CMC $37.92
- RVMD $29.17
- 52 Week High
- CMC $64.53
- RVMD $65.98
- Technical
- Relative Strength Index (RSI)
- CMC 55.14
- RVMD 77.00
- Support Level
- CMC $58.61
- RVMD $58.91
- Resistance Level
- CMC $61.67
- RVMD $66.00
- Average True Range (ATR)
- CMC 1.62
- RVMD 2.21
- MACD
- CMC 0.10
- RVMD 0.32
- Stochastic Oscillator
- CMC 75.62
- RVMD 85.24
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.